BridgeMD
Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated or not with intravitreal injections of aflibercept
EU CTIS ID: 2024-516681-10-01
What this study is testing
To compare the evolution of visual acuity between inclusion and the one-year visit in CRVO patients with PARS versus those without PARS.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient over 18
- Diagnosis of CRVO (central retinal vein occlusion), with or without macular edema.
- Naïve to intravitreal injection and intravitreal corticosteroid implant
- Member or beneficiary of a health insurance scheme
- Having received informed information about the study and having signed a consent form to participate in the study
- For women of childbearing age: commitment to effective contraception during aflibercept treatment and for at least 3 months after the last intravitreal injection of aflibercept
You likely can't join if
- Patient under legal protection
- Macular edema of etiology other than CRVO (central retinal vein occlusion)
- Active or suspected ocular or periocular infection
- Secondary exclusion criteria: ocular media opacities
- Secondary exclusion criteria: diabetic retinopathy
- Secondary exclusion criteria: administration of a drug other than aflibercept during the study
See the full eligibility criteria
- Patient over 18
- Diagnosis of CRVO (central retinal vein occlusion), with or without macular edema.
- Naïve to intravitreal injection and intravitreal corticosteroid implant
- Member or beneficiary of a health insurance scheme
- Having received informed information about the study and having signed a consent form to participate in the study
- For women of childbearing age: commitment to effective contraception during aflibercept treatment and for at least 3 months after the last intravitreal injection of aflibercept
- Onset of symptoms in previous month (maximum 30 days prior to inclusion)
- Patient under legal protection
- Macular edema of etiology other than CRVO (central retinal vein occlusion)
- Active or suspected ocular or periocular infection
- Secondary exclusion criteria: ocular media opacities
- Secondary exclusion criteria: diabetic retinopathy
- Secondary exclusion criteria: administration of a drug other than aflibercept during the study
- Severe intraocular inflammation
- Hypersensitivity to EYLEA® : to the active substance (aflibercept) or to one of the excipients
- Pregnant or breast-feeding women
- Previous stroke or myocardial infarction within the last 3 months
- Untreated retinal detachment or dehiscence
- Ocular media opacities
- Amblyopia
- Diabetic retinopathy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.